pancreaze
pancreaze: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.
pancreaze evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could pancreaze → VVUS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| VIVUS INC (VVUS) Exocrine pancreatic insufficiency (EPI) | Approved |
Clinical Trial Registry Records (1)
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors(The CF-FC Study)
Primary endpoint: Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving ZENPEP
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with pancreaze?
pancreaze has dated SEC/FDA relationship records for VIVUS INC.
How many clinical trials involve pancreaze?
BioSniper tracks 1 clinical trial involving pancreaze.
What is pancreaze's latest FDA decision?
The most recent tracked FDA decision for pancreaze is Approval for 1 INDICATIONS AND USAGE PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. PANCREAZE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ( 1 ), dated April 12, 2010.